Intensive Blood Pressure Lowering in Patients With Malignant Left Ventricular Hypertrophy.

Area of Science:

• Cardiology
• Hypertension Management
• Heart Failure Prevention

Background:

• Malignant left ventricular hypertrophy (LVH), characterized by cardiac biomarkers of injury and neurohormonal stress, signifies a high risk for heart failure and mortality.
• Identifying effective interventions for malignant LVH is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the impact of intensive systolic blood pressure (SBP) control on preventing malignant LVH and its associated adverse events.
• To assess the effects of intensive SBP lowering compared to standard control on heart failure events and mortality.

Main Methods:

• The SPRINT (Systolic Blood Pressure Intervention Trial) enrolled 8,820 participants categorized by baseline LVH (assessed by ECG) and cardiac biomarker levels.
• Participants were randomized to intensive vs. standard SBP lowering targets.
• Outcomes included rates of acute decompensated heart failure (ADHF), death, and the incidence/regression of malignant LVH.

Main Results:

• Intensive SBP lowering significantly reduced the incidence of malignant LVH (2.5% vs. 1.1%).
• The absolute risk reduction in the composite of ADHF events and death over 4 years was 4.4% for participants with baseline malignant LVH.
• Relative risk reductions for ADHF events and death were similar across groups, but absolute benefits were greater in those with malignant LVH.

Conclusions:

• Intensive SBP lowering is effective in preventing the development of malignant LVH.
• This intensive approach offers a substantial absolute risk reduction for the composite outcome of ADHF events and death in patients with pre-existing malignant LVH.